Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Paediatric rheumatology

Juvenile idiopathic arthritis—are biologic agents effective for pain?

Nature Reviews Rheumatology volume 9, pages 447–448 (2013)Cite this article

Subjects

Biologic medications are highly efficacious in juvenile idiopathic arthritis. However, a recent study found that a subgroup of children treated with anti-TNF agents had persistent pain despite good disease control. This finding highlights the importance of monitoring pain symptoms during treatment with modern DMARDs.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kimura, Y. & Walco, G. A. Treatment of chronic pain in pediatric rheumatic disease. Nat. Clin. Pract. Rheumatol. 3, 210–218 (2007).

    Article  CAS  Google Scholar 

  2. Anthony, K. K. & Schanberg, L. Pediatric pain syndromes and management of pain in children and adolescents with rheumatic diseases. Pediatr. Clin. N. Am. 52, 611–639 (2005).

    Article  Google Scholar 

  3. Lomholt, J. J., Thastum, M. & Herlin, T. Pain experience in children with juvenile idiopathic arthritis treated with anti-TNF agents compared to non-biologic standard treatment. Pediatr. Rheumatol. 11, 21 (2013).

    Article  Google Scholar 

  4. Ruperto, N. & Martini, A. Emerging drugs to treat juvenile idiopathic arthritis. Expert Opin. Emerg. Drugs 16, 493–505 (2011).

    Article  Google Scholar 

  5. Schanberg, L. et al. Daily pain and symptoms in children with polyarticular arthritis. Arthritis Rheum. 48, 1390–1397 (2003).

    Article  Google Scholar 

  6. Prince, F. H. M. et al. Major improvements in health-related quality of life in during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann. Rheum. Dis. 69, 138–142 (2010).

    Article  CAS  Google Scholar 

  7. Ruperto, N. et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 62, 1542–1551 (2010).

    Article  Google Scholar 

  8. Brunner, H. I. & Ravelli, A. Developing outcome measures for paediatric rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 23, 609–624 (2009).

    Article  Google Scholar 

  9. Garcia-Munitis, P. et al. Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis Rheum. 55, 177–183 (2006).

    Article  Google Scholar 

  10. Sherry, D. D., Bohnsack, J., Salmonson K., Wallace, C. A. & Mellins, E. Painless juvenile rheumatoid arthritis. J. Pediatr. 116, 921–923 (1990).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Giannina Gaslini and Università degli Studi di Genova, Largo G. Gaslini 5, 16147, Genova, Italy

    Alessandro Consolaro & Angelo Ravelli

Authors
  1. Alessandro Consolaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelo Ravelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Ravelli.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Consolaro, A., Ravelli, A. Juvenile idiopathic arthritis—are biologic agents effective for pain?. Nat Rev Rheumatol 9, 447–448 (2013). https://doi.org/10.1038/nrrheum.2013.108

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.108

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research